Sign In
Buy ELDN
$3.81
-0.110 (-2.81%)
At Close: Jun 22, 2026
Penny Stock Picks: 3 Companies Poised to Graduate to the Big Leagues
09:36am, Monday, 17'th Jun 2024
Penny stocks sometimes get a bad rep due to their inherent risk. They are cheap but are considered highly volatile and have a low chance of providing substantial profit.
3 High-Potential Penny Stocks to Turn $1000 into $1 Million: June 2024
03:18pm, Tuesday, 11'th Jun 2024
Even if they're labeled as millionaire-maker penny stocks, you must remember one thing: this sector is extremely dangerous. When you're dealing with incredibly small market capitalization firms, anyth
Data from 13 participants presented at the American Transplant Congress continue to support safety and tolerability profile of tegoprubart Overall mean eGFR of all reported time points after day 30 po
Eledon Pharmaceuticals (ELDN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
10:56am, Monday, 27'th May 2024
Eledon Pharmaceuticals (ELDN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreeme
Eledon Pharmaceuticals, Inc. (ELDN) is a Great Momentum Stock: Should You Buy?
01:01pm, Wednesday, 22'nd May 2024
Does Eledon Pharmaceuticals, Inc. (ELDN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Eledon Pharmaceuticals (ELDN) Moves to Buy: Rationale Behind the Upgrade
01:01pm, Tuesday, 14'th May 2024
Eledon Pharmaceuticals (ELDN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results
07:30am, Thursday, 09'th May 2024
Completed oversubscribed $50 million private placement First participant dosed in clinical trial at University of Chicago Medicine assessing the use of tegoprubart to prevent islet cell transplant rej
IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that the Company will participate in the American Transplant Congress (ATC)
Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection
07:05am, Tuesday, 07'th May 2024
First participant dosed in clinical trial at University of Chicago Medicine assessing the use of tegoprubart to prevent islet cell transplant rejection in patients with type 1 diabetes Company reports
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
04:01pm, Thursday, 28'th Mar 2024
Enrolled 12 participants in Phase 2 BESTOW trial evaluating tegoprubart for the prevention of kidney rejection Tegoprubart used as a component of the immunosuppressive treatment regimen following the
IRVINE, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the enrollment of the 12th participant on March 23, 2024, in the Company'
Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human
10:31am, Thursday, 21'st Mar 2024
Historic kidney xenotransplantation procedure conducted at Massachusetts General Hospital Tegoprubart administration has now been used investigationally to prevent rejection in both kidney and heart p
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:01pm, Tuesday, 13'th Feb 2024
IRVINE, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that the Company's Compensation Committee granted 42,500 restricted stock
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook
04:40pm, Thursday, 04'th Jan 2024
Reported updated data from ongoing Phase 1b trial in kidney transplantation demonstrating tegoprubart treatment successfully prevented kidney transplant rejection and was generally safe and well-toler
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06:00pm, Monday, 04'th Dec 2023
IRVINE, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that on December 1, 2023, the Company's Compensation Committee granted our
